Dr Matthew Ware completed his bachelor's and master's degrees at Swansea before enrolling on collaborative PhD in nanotechnology with Houston Methodist Research Institute in Texas - one of the initiatives to come out of the Texas Strategic Partnership. 

Swansea’s Texas Strategic Partnership encompasses eight leading universities and health institutions and has twice been shortlisted for a Times Higher Education and Management Award (THELMA).  It is distinctive because of the breadth and depth of research, teaching and mobility activities which reach across all of the University's academic Colleges, bringing benefits to both staff and students.

After graduating, Dr Ware remained in Texas, researching new treatments for pancreatic and hepatic cancers at Baylor College of Medicine. His research resulted in two patents, including the CorleyWare Device - a new intra-operative device to treat portions of cancer that cannot be removed by a surgeon’s scalpel. 

Headshot of Matthew Ware

In summer 2018, Dr Ware took up a new role as a scientist for Celgene, a biotechnology company that discovers, develops and commercialises medicines for cancer and inflammatory disorders. Since November 2019, Dr Ware has worked at Bristol Myers-Squibb as a scientist, to deliver better medicines for patients with cancer.